-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 1st, May 27th, by the "China Enterprise News" group, the special issue department of the Consumer Daily, the "Discover Brand" column group, the online version of the People's Daily Market News Brand Power Country · Independent Brand Optimization Demonstration Project, and external The China International Brand Strategy Research Center of the University of Economics and Business and other units jointly sponsored the 2021 (eighth) Chinese brand influence evaluation results release event held in Beijing.
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
With the theme of "Developing the Brand Economy and Promoting the Optimization and Upgrade of the Economic System", this event invites leaders and experts in different fields to focus on quality improvement actions, brand innovation and development, and foster new technologies, new products, new formats, and new models.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
Innovative Research collateral disease theory in recent years, traditional Chinese medicine inheritance and innovation model.
For many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
For many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
In recent years, Yiling Pharmaceutical development into the fast lane, one of China's listed companies in the market value of 500, the top 500 most valuable brands in China, Chinese medicine enterprises Top10, Chinese medicine listed companies in the top 20 list, etc.
have significant influence, medicine Industry influence continues to grow.
have significant influence, medicine Industry influence continues to grow.
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
Among them, the subsidiary Hebei Yiling Medical Research Institute as the first main research unit completed the "Traditional Chinese Medicine Vein Theory Construction and Its Guidance for the Prevention and Treatment of Microvascular Diseases" project involving the three major products of Tongxinluo, Shensongyangxin and Qiliqiangxin.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
In addition, Yiling Pharmaceutical's respiratory system products have become Chinese patent medicines for colds.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
At present, the company's many Chinese medicine varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries.
Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
Medical Network News, June 1st, May 27th, by the "China Enterprise News" group, the special issue department of the Consumer Daily, the "Discover Brand" column group, the online version of the People's Daily Market News Brand Power Country · Independent Brand Optimization Demonstration Project, and external The China International Brand Strategy Research Center of the University of Economics and Business and other units jointly sponsored the 2021 (eighth) Chinese brand influence evaluation results release event held in Beijing.
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
With the theme of "Developing the Brand Economy and Promoting the Optimization and Upgrade of the Economic System", this event invites leaders and experts in different fields to focus on quality improvement actions, brand innovation and development, and foster new technologies, new products, new formats, and new models.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
Innovative Research collateral disease theory in recent years, traditional Chinese medicine inheritance and innovation model.
For many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
For many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
In recent years, Yiling Pharmaceutical development into the fast lane, one of China's listed companies in the market value of 500, the top 500 most valuable brands in China, Chinese medicine enterprises Top10, Chinese medicine listed companies in the top 20 list, etc.
have significant influence, medicine Industry influence continues to grow.
have significant influence, medicine Industry influence continues to grow.
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
Among them, the subsidiary Hebei Yiling Medical Research Institute as the first main research unit completed the "Traditional Chinese Medicine Vein Theory Construction and Its Guidance for the Prevention and Treatment of Microvascular Diseases" project involving the three major products of Tongxinluo, Shensongyangxin and Qiliqiangxin.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
In addition, Yiling Pharmaceutical's respiratory system products have become Chinese patent medicines for colds.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
At present, the company's many Chinese medicine varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries.
Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
Medical Network News, June 1st, May 27th, by the "China Enterprise News" group, the special issue department of the Consumer Daily, the "Discover Brand" column group, the online version of the People's Daily Market News Brand Power Country · Independent Brand Optimization Demonstration Project, and external The China International Brand Strategy Research Center of the University of Economics and Business and other units jointly sponsored the 2021 (eighth) Chinese brand influence evaluation results release event held in Beijing.
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
Yiling Pharmaceutical was invited to attend and won the "2021 Chinese Brand (Industry) Top Ten Innovations" Power enterprise".
With the theme of "Developing the Brand Economy and Promoting the Optimization and Upgrade of the Economic System", this event invites leaders and experts in different fields to focus on quality improvement actions, brand innovation and development, and foster new technologies, new products, new formats, and new models.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
In-depth discussions and docking services were launched to provide strong support and development guidance for Chinese brand building.
Innovative Research collateral disease theory in recent years, traditional Chinese medicine inheritance and innovation model.
For many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
TCM Chinese medicine TCM drugs drugs drugsFor many years, Yiling Pharmaceutical has always adhered to the original innovation as the forerunner, organized experts to increase scientific research, systematically built a theoretical system of collateral disease, and committed to using Tongluo Chinese medicine to prevent and treat cardiovascular and cerebrovascular diseases, respiratory diseases, diabetes, tumors, etc.
continuing disease research, development patent drugs kinds of more than 10, of which 8 included in the national medical insurance catalog, five for the country-based drug types, forming a series of patented drugs in various stages of development of the cluster.
In recent years, Yiling Pharmaceutical development into the fast lane, one of China's listed companies in the market value of 500, the top 500 most valuable brands in China, Chinese medicine enterprises Top10, Chinese medicine listed companies in the top 20 list, etc.
have significant influence, medicine Industry influence continues to grow.
Enterprise Enterprise Enterprise Medicine Pharmaceutical Medicinehave significant influence, medicine Industry influence continues to grow.
The company developed Tongxinluo Capsules, Shensong Yangxin Capsules, Qiliqiangxin Capsules, Lianhua Qingwen Capsules (granules), Lianhua Qingke Tablets, Yangzheng Xiaoji Capsules, Jinlida Granules, Bazi Bushen Innovative patented Chinese medicines such as capsules have carried out evidence-based medical research, and have been included in the disease diagnosis and treatment guidelines and expert consensus issued by the Chinese Medical Association and the Chinese Association of Integrative Medicine.
Among them, the subsidiary Hebei Yiling Medical Research Institute as the first main research unit completed the "Traditional Chinese Medicine Vein Theory Construction and Its Guidance for the Prevention and Treatment of Microvascular Diseases" project involving the three major products of Tongxinluo, Shensongyangxin and Qiliqiangxin.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
Won the first prize of National Science and Technology Progress Award in 2019, which is the only first prize of national science and technology progress in the medical and health industry that year, which has greatly improved the company's academic brand.
In addition, Yiling Pharmaceutical's respiratory system products have become Chinese patent medicines for colds.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
Take Lianhua Qingwen Capsules as an example.
As one of the "three medicines and three prescriptions" recommended at the national level, it has played a huge role since the outbreak of the new crown pneumonia and has become a Chinese patent medicine with a higher frequency of recommendation.
Up to now, Lianhua Qingwen Capsules have been approved for marketing in more than 20 countries and regions including Canada, Russia, and the Philippines, and have played an important role in global epidemic prevention and control.
Previously, the National Medical Security Administration and the Ministry of Human Resources and Social Security issued the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)", and Yiling Pharmaceutical's innovative patent Chinese medicine Lianhuaqing was approved for listing in May 2020.
Cough tablets were selected as a category B medical insurance product.
As the "sister medicine" of Lianhua Qingwen Capsules/granules, this medicine will bring good news to more patients with acute tracheobronchitis.
At present, the company's many Chinese medicine varieties have been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries.
Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
Chinese Medicine Chinese Medicine Chinese Medicine Under the “Belt and Road” initiative, the curative effect of Chinese medicine has been recognized by countries and regions along the route, especially in this epidemic, which has deepened the understanding of Chinese medicine by the people of the world.
Yiling Pharmaceutical said that in the future, the company will continue to inherit the essence, maintain integrity, innovation, openness and sharing, strengthen international cooperation, and promote Chinese medicine to the world.
